D.E. Shaw & Co
TERN

D.E. Shaw & Co’s Terns Pharmaceuticals TERN Stock Holding History

D.E. Shaw & Co’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.6M Sell
201,191
-952,838
-83% -$39.1M 0.01% 1585
2025
Q4 		$46.6M Buy
+1,154,029
New +$26.7M 0.03% 750
2025
Q1 		– Sell
-57,341
Closed -$318K – 4743
2024
Q4 		$318K Buy
57,341
+19,870
+53% +$135K ﹤0.01% 3860
2024
Q3 		$313K Buy
37,471
+10,506
+39% +$86.4K ﹤0.01% 3959
2024
Q2 		$184K Buy
26,965
+9,175
+52% +$55.6K ﹤0.01% 4090
2024
Q1 		$117K Buy
+17,790
New +$116K ﹤0.01% 3994
2023
Q2 		– Sell
-46,762
Closed -$554K – 4547
2023
Q1 		$554K Buy
+46,762
New +$447K ﹤0.01% 3510

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

D.E. Shaw & Co's TERN Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Terns Pharmaceuticals (TERN) stake by 83% in Q1 2026, selling an estimated $39.1M and leaving 201,191 shares worth $10.6M. The position accounts for 0.01% of the portfolio, ranked #1585.

D.E. Shaw & Co first reported a position in TERN in Q1 2023 and has held it in 7 quarters since. The position peaked at $46.6M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • D.E. Shaw & Co held 201,191 shares of Terns Pharmaceuticals worth $10.6M as of Q1 2026.
  • D.E. Shaw & Co sold 952,838 Terns Pharmaceuticals shares in Q1 2026, an estimated $39.1M.
  • Terns Pharmaceuticals made up 0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #1585 holding.
  • D.E. Shaw & Co first reported a position in Terns Pharmaceuticals in Q1 2023 and has held it in 7 quarters since.
  • D.E. Shaw & Co's Terns Pharmaceuticals position peaked at $46.6M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.